QT Imaging Secures UAE Regulatory Clearance for Breast Acoustic CT Scanner
Event summary
- QT Imaging's Breast Acoustic CT™ scanner received regulatory clearance from the UAE Emirates Drug Establishment (EDE) on March 24, 2026.
- The clearance allows for importation, distribution, and marketing of the scanner in the UAE through EDE-licensed medical warehouses.
- QT Imaging signed an exclusive distribution agreement with Al Naghi Medical Co. in January 2026, establishing a $24 million revenue pipeline through 2028.
- Breast cancer accounts for 25% of all cancer cases in the UAE, highlighting the market need for advanced imaging solutions.
The big picture
QT Imaging's regulatory clearance in the UAE is a strategic milestone that reinforces its commitment to expanding access to advanced, radiation-free breast imaging technology. The clearance complements its existing presence in Saudi Arabia, positioning the company to build strong partnerships with leading healthcare providers in the Middle East. With breast cancer accounting for a significant portion of cancer cases in the UAE, the market demand for safe and effective imaging solutions is urgent, making this clearance a critical step in QT Imaging's global commercialization efforts.
What we're watching
- Market Penetration
- How QT Imaging will leverage its regulatory clearance to accelerate commercial deployment in the UAE and Saudi Arabia.
- Revenue Growth
- Whether the $24 million revenue pipeline through 2028 with Al Naghi Medical Co. will materialize as planned.
- Regulatory Strategy
- The pace at which QT Imaging can navigate and secure regulatory approvals in other key international markets.